Liu, Y. (2018) Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: a case report and literatures review. Cancer Biol. Ther. 19, 445-449LIU Y. Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: acase report and literatures review[J]. Cancer ...
Small cell lung cancerTKIsResistanceNon-small cell lung cancer (NSCLC) transforming to small cell lung cancer (SCLC) is one of the mechanisms of resistance to tyrosine kinase inhibitors (TKIs). Cases of NSCLC transforming into SCLC have been discovered. However, we lack concentrated data on the...
Combined small cell lung cancer (cSCLC) is relatively unusual. We report a case of cSCLC in a 78-year-old man with no prior medical history who presented for evaluation of right upper lobe (RUL) lung mass. A CT scan showed a 3.0 × 2.5 × 2.3 cm RUL lung mass with mildly prominent...
et al. A phase 1b study evaluating the combination of sotorasib, a KRASG12C inhibitor, and afatinib, a pan-ErbB tyrosine kinase inhibitor, in advanced KRAS p.G12C mutated non-small cell lung cancer (NSCLC). Mol. Cancer Ther. 20, abstr. P05-02 (2021. NCT04185883: Sotorasib ...
Non-small cell lung cancer (NSCLC) is known to have poor patient outcomes due to development of resistance to chemotherapy agents and the EGFR inhibitors, which results in recurrence of highly aggressive lung tumors. Even with recent success in immunothe
Lung small cell carcinoma and lung adenocarcinomadetected concomitantly by transbronchial brushing cytology YAMAZAKI Kohichi , OGURA Shigeaki , ISOBE Hiroshi , AKITA Hirotoshi , ABE Shosaku , ARAKAWA Mikio , NOJIMA Takayuki , KAWAKAMI Yoshikazu The Journal of the Japanese Society of Clinical Cytology 33...
Lung cancer is the leading cause of cancer death and its incidence is ranked high in men and women worldwide. Non-small-cell lung cancer (NSCLC) adenocarcinoma is one of the most frequent histological subtypes of lung cancer. The aberration profile and the molecular mechanism driving its progres...
Primary lung cancer is the leading cause of cancer-related mortality worldwide, and non–small-cell lung cancer accounts for about 85% of all lung cancers, of which approximately 70% are adenocarcinomas. Lung adenocarcinoma is a radiologically, histomorphologically, molecularly, and clinically heterog...
While a recent phase III trial of tiragolumab as first line therapy in small cell lung cancer was unsuccessful68, the Morpheus-Pancreatic Cancer trial (NCT03193190) is investigating the effect of TIGIT blockage in metastatic PDAC and will hopefully provide more insight into the clinical relevance ...
D. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 381, 2020–2031 (2019). Article CAS PubMed Google Scholar Liu, T. et al. First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and ...